685 results on '"Toes, René E. M."'
Search Results
2. Anti-carbamylated protein antibodies in systemic sclerosis
3. Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations
4. A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis
5. Glycobiology of rheumatic diseases
6. Neutrophil Depletion Changes the N-Glycosylation Pattern of IgG in Experimental Murine Sepsis
7. A whole blood-based functional assay to characterize immunoglobulin A effector functions
8. Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts
9. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial
10. Absence of Epstein-Barr virus DNA in anti-citrullinated protein antibody-expressing B cells of patients with rheumatoid arthritis
11. Immune response to post-translationally modified proteins in rheumatoid arthritis: what makes it special?
12. Author Correction: Glycobiology of rheumatic diseases
13. Type 17-specific immune pathways are active in early spondyloarthritis
14. IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis
15. Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load
16. IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis.
17. Adaptive antibody diversification through N -linked glycosylation of the immunoglobulin variable region
18. IgG Fab Glycans Hinder FcRn-Mediated Placental Transport
19. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs
20. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response
21. Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association.
22. Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies
23. IgG Fab Glycans Hinder FcRn-Mediated Placental Transport
24. Additional file 1 of Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations
25. Bridging Autoantibodies and Arthritis: The Role of Fc Receptors
26. Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis.
27. Glycobiology of rheumatic diseases
28. Comparative Photoaffinity Profiling of Omega-3 Signaling Lipid Probes Reveals Prostaglandin Reductase 1 as a Metabolic Hub in Human Macrophages
29. At Critically Low Antigen Densities, IgM Hexamers Outcompete Both IgM Pentamers and IgG1 for Human Complement Deposition and Complement-Dependent Cytotoxicity
30. Benchmarking computational methods for B-cell receptor reconstruction from single-cell RNA-seq data
31. Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation
32. Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes
33. At Critically Low Antigen Densities, IgM Hexamers Outcompete Both IgM Pentamers and IgG1 for Human Complement Deposition and Complement-Dependent Cytotoxicity
34. Cross-reactivity of anti-modified protein antibodies is also present in predisease and individuals without rheumatoid arthritis
35. In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis
36. In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis.
37. Decreased serum cell-free DNA levels in rheumatoid arthritis
38. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage
39. Protective Effect of Noninherited Maternal HLA-DR Antigens on Rheumatoid Arthritis Development
40. The pathogenic potential of autoreactive antibodies in rheumatoid arthritis
41. Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis
42. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis
43. Serum Levels of Tryptase Suggest That Mast Cells Might Have an Antiinflammatory Role in Rheumatoid Arthritis: Comment on the Article by Rivellese et al
44. The MHC Expression of Dendritic Cells from Mouse Spleen Isolated by Centrifugal Elutriation is Upregulated During Short Term Culture
45. Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA
46. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis
47. Ability of Interleukin-33– and Immune Complex–Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses
48. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities
49. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis
50. Bridging Autoantibodies and Arthritis: The Role of Fc Receptors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.